Weight Loss Market (2026-2036)

The growth of this market is mainly driven by the rising global prevalence of obesity and overweight, the clinical effectiveness and rapid uptake of incretin-based pharmacotherapy, the extension of insurance and public reimbursement to obesity treatment, the reclassification of obesity as a chronic disease requiring long-term management, and the very large share of obesity that remains untreated. However, steep price reductions negotiated by payers and governments, poor treatment persistence and high discontinuation rates, supply and manufacturing constraints on incretin products, and the displacement of surgical and device procedures by pharmacotherapy restrain the growth of this market.

Furthermore, oral small-molecule weight loss drugs, public payer coverage of obesity treatment, nutrition and muscle-preservation products designed for patients on incretin therapy, and expansion into emerging markets with rising obesity prevalence are expected to offer growth opportunities for the stakeholders in this market. However, the limited readiness of national health systems to deliver obesity care, long-term safety and muscle-loss concerns, compounded and counterfeit product proliferation, and weight regain following treatment discontinuation remain major challenges impacting the growth of this market. Additionally, the shift from injectable to oral administration, combination therapies targeting multiple incretin pathways, the integration of digital and telehealth delivery with pharmacotherapy, and the convergence of weight loss with cardiometabolic outcome indications are prominent trends in this market.

The Weight Loss Market comprises the products and services used to achieve and maintain clinically meaningful weight reduction in people living with overweight and obesity. The market covers weight loss pharmacotherapy, including glucagon-like peptide-1 receptor agonists, dual and triple incretin agonists, oral small-molecule agents, and earlier anti-obesity drug classes; nutrition and meal replacement, including meal replacement shakes, bars and prepared plans, weight-management foods and beverages, protein and micronutrient products, and dietary supplements; devices and surgical products, including bariatric surgical devices, endoscopic and space-occupying systems, and gastric electrical stimulation; and services and programmes, including commercial weight loss programmes, physician-supervised and clinical nutrition services, digital and telehealth platforms, and behavioural counselling. Market value is measured at manufacturer and provider revenue, counts only the obesity-indicated portion of incretin product sales, and excludes diabetes-indicated prescriptions, general fitness equipment and gymnasium memberships purchased for broader wellness reasons, and the facility and professional fees for bariatric surgery itself. The ecosystem spans pharmaceutical and biotechnology companies, contract manufacturers of injectable and oral dose forms, nutrition and supplement manufacturers, medical device makers, retail and specialty pharmacies, telehealth platforms, employers and payers, and the clinicians and dietitians who deliver care.

The epidemiological base of this market continues to widen. The World Obesity Federation projects in the World Obesity Atlas 2025 that the number of adults living with obesity will rise more than 115% between 2010 and 2030, from 524 million to 1.13 billion, and that adults with class II obesity and above, defined as a body mass index over 35 kilograms per square metre, will rise from 157 million in 2010 to 385 million in 2030, an increase of 145.2%. Growth is fastest outside the established high-prevalence markets, with class II obesity and above projected to rise 301.1% in South-East Asia, 362.4% in the Western Pacific, 215.3% in Africa, and 214.8% in the Eastern Mediterranean over the same period. The clinical burden is already substantial, with 1.6 million premature deaths before age 70 from non-communicable diseases directly attributable to high body mass index in 2021, and 44 million of the 161 million adult years lived with avoidable non-communicable disease ill-health, or 27%, attributed to high body mass index, rising to 55% for type 2 diabetes.

Pharmacotherapy has reshaped the structure of this market. Novo Nordisk reported obesity care sales of DKK 59,902 million for the first nine months of 2025, up 37% in Danish kroner and 41% at constant exchange rates, within which Wegovy contributed DKK 57,242 million, up 49%, while Saxenda declined 51% to DKK 2,660 million as prescribing moved to newer agents. Eli Lilly reported Zepbound revenue of USD 13.54 billion for 2025, up 175%, alongside Mounjaro revenue of USD 22.97 billion, up 99%. These products have also changed the relative position of other interventions: data presented by the American Society for Metabolic and Bariatric Surgery in May 2026 show that in a cohort of patients with severe obesity and without diabetes, GLP-1 prescriptions rose from 4,592 in 2018 to 1,421,202 in 2025, while bariatric surgeries in the same cohort fell from 42,615 in 2023 to 33,429 in 2025.

Access and pricing are being restructured simultaneously. Under agreements announced in November 2025, Medicare is to cover obesity medicines for the first time from mid-2026 through a pilot programme, with copays of USD 50 a month for eligible patients, qualification based on a body mass index above 27 together with prediabetes or established cardiovascular disease, and about 10% of Medicare beneficiaries expected to qualify. Medicare and Medicaid are to pay USD 245 a month for non-starting doses, oral starting doses were set at USD 145 to USD 150 a month across Medicare, Medicaid and the TrumpRx platform launched in January 2026, and injectables purchased directly from manufacturers were set at about USD 350 a month declining to USD 245 over two years, against list prices of USD 1,000 to USD 1,350 a month. The forecast therefore assumes rapid volume expansion against falling realised prices per patient, strong growth in oral agents, continued nutrition and services demand from the growing treated population, and slower growth in surgical and device interventions through 2036.